Bellevue Life Sciences Acquisition Appoints Sang Hyun Kim as Director

OSR Holdings, Inc.

Appointed Sang Hyun Kim as director effective June 23, 2024; fills Audit, Compensation, and M&A Committee vacancies.
Mr. Kim is Special Advisor of Marketing, Private Equity Funds at Korea Daesung Asset Management Co., Ltd.
Has ~11 years at Samsung Group including Global M&A Strategy at Samsung Asset Management.
Board determined Mr. Kim meets Nasdaq independence standards; no compensation for director role.
Mr. Kim entered into standard Letter Agreement and Indemnity Agreement with BLAC.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sang Hyun Kim

Director

OSRH · OSR Holdings, Inc.

Effective: 2024-06-23
Filed: June 27, 2024, 7:59 PM ET

On June 23, 2024, the Board of Directors (the “Board”) of Bellevue Life Sciences Acquisition Corp. (the “Company”) appointed Mr. Sang Hyun Kim as a director, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sang Hyun Kim was appointed as Director at OSR Holdings, Inc..

Action: appointed
Role: Director

Exact text from the filing

On June 23, 2024, the Board of Directors (the “Board”) of Bellevue Life Sciences Acquisition Corp. (the “Company”) appointed Mr. Sang Hyun Kim as a director, effective immediately.

View on SEC.gov

OSR Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-169795

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.